Kexing Biopharm Co., Ltd. (SHA:688136)

The Shyft Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	491.04	554.56	568.8	785.38	877.62	1,103
Cash & Short-Term Investments	576.27	554.56	568.8	785.38	877.62	1,103
Cash Growth	6.27%	-2.50%	-27.58%	-10.51%	-20.41%	630.43%
Accounts Receivable	590.42	563.82	342.04	387.44	382.62	407.86
Other Receivables	17.21	15.9	4.45	3.25	2.84	5.34
Receivables	607.63	579.72	346.49	390.69	385.46	413.2
Inventory	126.21	141.81	191.36	208.18	172.16	113.38
Other Current Assets	13.82	11.72	26.97	27.06	25.57	14.69
Total Current Assets	1,324	1,288	1,134	1,411	1,461	1,644
Property, Plant & Equipment	1,160	1,177	1,200	1,053	936.24	585.86
Long-Term Investments	19.76	203.41	245.32	15	247.46	-
Other Intangible Assets	219.61	225.14	158.72	165.82	26.96	36.85
Long-Term Accounts Receivable	-	-	-	0.31	-	-
Long-Term Deferred Tax Assets	112.66	117.22	133.98	80.83	12.1	3.75
Long-Term Deferred Charges	53.72	50.37	3.08	-	21.82	14.69
Other Long-Term Assets	304.27	101.02	156.61	438.91	123.64	81.55
Total Assets	3,194	3,162	3,031	3,165	2,829	2,367
Accounts Payable	180.09	71.91	56.02	67.78	65.73	41.23
Accrued Expenses	26.07	112.98	84.14	92.89	97.63	88.32
Short-Term Debt	267.19	269.12	120.7	162.69	276.26	204.57
Current Portion of Long-Term Debt	350.22	313.25	275.03	51.78	-	1.36
Current Portion of Leases	-	12.45	6.7	19.87	18.39	15.6
Current Income Taxes Payable	5.01	-	-	-	-	-
Current Unearned Revenue	11.19	9.78	20.44	17.99	7.16	4.76
Other Current Liabilities	42.49	96.91	106.97	126.36	138.44	84.86
Total Current Liabilities	882.26	886.4	669.99	539.37	603.61	440.7
Long-Term Debt	620.93	611.18	695.84	779.23	263.37	94.19
Long-Term Leases	12.56	14.78	17.79	24.96	43.25	-
Long-Term Unearned Revenue	3.02	3.15	5.32	0.75	0.99	1.61
Long-Term Deferred Tax Liabilities	7.04	7.48	11.36	14.55	7.12	-
Total Liabilities	1,526	1,523	1,400	1,359	918.34	536.5
Common Stock	199.64	199.64	199.2	198.7	198.7	198.7
Additional Paid-In Capital	1,292	1,288	1,282	1,274	1,266	1,266
Retained Earnings	202.36	176.78	145.3	335.59	445.76	365.19
Treasury Stock	-31.12	-31.12	-	-	-	-
Comprehensive Income & Other	1.11	1.11	-0.01	-	-	-
Total Common Equity	1,664	1,635	1,626	1,808	1,911	1,830
Minority Interest	3.61	4.34	4.77	-2.53	-	-
Shareholders' Equity	1,668	1,639	1,631	1,806	1,911	1,830
Total Liabilities & Equity	3,194	3,162	3,031	3,165	2,829	2,367
Total Debt	1,251	1,221	1,116	1,039	601.27	315.72
Net Cash (Debt)	-674.62	-666.22	-547.26	-253.16	276.35	786.93
Net Cash Growth	-	-	-	-	-64.88%	-
Net Cash Per Share	-3.43	-3.39	-2.76	-1.26	1.40	5.26
Filing Date Shares Outstanding	197.76	197.76	199.2	198.7	198.7	198.7
Total Common Shares Outstanding	197.76	197.76	199.2	198.7	198.7	198.7
Working Capital	441.68	401.41	463.63	871.94	857.2	1,203
Book Value Per Share	8.42	8.27	8.16	9.10	9.62	9.21
Tangible Book Value	1,445	1,410	1,467	1,643	1,884	1,793
Tangible Book Value Per Share	7.31	7.13	7.37	8.27	9.48	9.03
Buildings	-	754.25	662.95	609.2	361.78	354.23
Machinery	-	514.22	370.42	326.3	243.82	198.49
Construction In Progress	-	176.82	372.56	256.57	428.52	168.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.